Trial · NCT04914741
A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)
NCT04914741, Phase 1, Phase 2, Unknown, Peter MacCallum Cancer Centre, Australia
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL). Trials, record NCT04914741. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04914741
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)
- NCT number
- NCT04914741
- Status
- Unknown
- Phases
- Phase 1, Phase 2
- Enrollment
- 80 participants, actual
- Lead sponsor
- Peter MacCallum Cancer Centre, Australia
- Conditions
- Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
- Interventions
- Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, Glofitamab, Polatuzumab vedotin
- First posted
- 2021-06-07
- Last updated
- 2024-08-12
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | To assess safety of the combination of glofitamab and R-CHOP or pola-RCHP according to number of participants with treatment-related adverse events | From start of treatment till the end of study, assessed up to approximately 60 months | |
| Primary | To evaluate the Relative Dose Intensity (RDI) of the chemotherapy backbone | From start of study treatment till the end of study treatment, assessed up to approximately 12 months | |
| Primary | To evaluate the rates of early chemotherapy discontinuation | From start of study treatment till the end of study treatment, assessed up to approximately 12 months | |
| Secondary | To estimate the proportion of patients achieving a complete response (CR) after cycles 2, 4 and at end of induction treatment (6 cycles) of the novel combination therapy according to Lugano 2014 criteria | Up to approximately 6 months (each cycle is 21 days) | |
| Secondary | To estimate overall response rate (ORR) | Up to approximately 6 months (each cycle is 21 days) | |
| Secondary | To describe progression free survival (PFS) | From first dose of chemotherapy induction to first date of objectively documented progressive disease or date of death of any cause, whichever occurs first, assessed up to approximately 60 months | |
| Secondary | To describe the duration of response (DoR) measured in the subset of patients who achieved CR or PR | Time from the first documented disease response to the date of progressive disease or death, whichever occurs first, assessed up to approximately 60 months | |
| Secondary | Overall survival (OS) as defined as the time from first dose of chemotherapy induction to the date of death from any cause | From first dose of chemotherapy induction to the date of death from any cause, assessed up to approximately 60 months | |
| Other | Correlation between circulating tumour DNA detection and response (CR and ORR) | From start of treatment till end of study assessed up to 60 months | |
| Other | Comparison of efficacy (rates of CR, ORR, DOR, PFS and OS) between the two study arms | From start of treatment till end of study assessed up to 60 months |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04914741
GET https://conductscience.org/api/trials/v1/NCT04914741/registered